Trial Profile
Phase Ib trial (ex-US) of oral exenatide [ORMD 0901] for type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2016
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 29 Nov 2016 Status changed from recruiting to completed, according to an Oramed Pharmaceuticals media release.
- 06 Jan 2016 As per an Oramed Pharmaceuticals media release, data from this trial is expected upon completion of this trial in the first quarter of 2016.
- 06 Jan 2016 Status changed from planning to recruiting, as per Oramed Pharmaceuticals media release.